Anthropic has announced the appointment of Vas Narasimhan to its Board of Directors, a move facilitated by the Anthropic Long-Term Benefit Trust. Narasimhan, who serves as the CEO of Novartis, brings extensive experience in the healthcare sector, aligning with Anthropic's vision of leveraging AI to enhance human life.
Expertise in Healthcare: Narasimhan's background as a physician-scientist and his leadership at Novartis, where he has overseen the development of over 35 novel medicines, positions him uniquely to contribute to Anthropic's mission. Daniela Amodei, Co-founder and President of Anthropic, expressed gratitude for his addition, emphasizing the importance of safely scaling new technologies.
Board Composition: With Narasimhan's appointment, the Long-Term Benefit Trust now holds a majority on the Board. This Trust operates independently, ensuring that Anthropic maintains a balance between financial success and its public benefit mission.
Commitment to Responsible Innovation: Neil Shah, Chair of the Long-Term Benefit Trust, highlighted the importance of Narasimhan's perspective in guiding the company as it develops significant technologies. His career has been dedicated to advancing science responsibly, making him an ideal fit for the Board.
Narasimhan's Vision: In his statement, Narasimhan remarked on the transformative potential of technology in healthcare, particularly through AI. He expressed his honor in joining Anthropic and contributing to its mission of setting standards for responsible AI development.
Background Highlights: Narasimhan has a rich history in global health, having worked on programs addressing HIV/AIDS, malaria, and tuberculosis across various continents. He is also a member of the US National Academy of Medicine and serves on multiple prestigious boards.
Additionally, Anthropic is launching the Claude Partner Network, aimed at assisting organizations in adopting its AI technology.
